Schizophrenia Market to Gain Momentum During the Forecast Period (2026-2036), with Growing Pipeline of Novel and Long-Acting Therapies | DelveInsight
The schizophrenia market is expected to showcase significant growth driven by rising disease prevalence, the expanding market for approved therapies, and the anticipated launch of new schizophrenia treatments such as Olanzapine LAI (TEV-44749/mdc-TJK; Teva Pharmaceutical/MedinCell/Royalty Pharma), Ulotaront (SEP-363856; Sumitomo Pharma/Otsuka Pharmaceuticals), Brilaroxazine (RP-5063; Reviva Pharmaceuticals), and others during the forecast period.
LAS VEGAS, Oct. 7, 2026 /PRNewswire/ -- Recently published Schizophrenia Market Insights report includes a comprehensive understanding of current treatment practices, emerging schizophrenia drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Schizophrenia Market Summary
Discover FDA approved medications for schizophrenia with brand and generic names 2026 @ https://www.delveinsight.com/report-store/schizophrenia-market
Key Factors Driving the Growth of the Schizophrenia Market
Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that the market for schizophrenia drugs is driven by increasing demand for long-acting antipsychotic medications, along with the emergence of new molecules in development.
Schizophrenia Market Analysis
Schizophrenia Competitive Landscape
Some of the schizophrenia medications under development include Olanzapine LAI (TEV-44749/mdc-TJK; Teva Pharmaceutical/MedinCell/Royalty Pharma), Ulotaront (SEP-363856; Sumitomo Pharma/Otsuka Pharmaceuticals), Brilaroxazine (RP-5063; Reviva Pharmaceuticals), Roluperidone (MIN-101/MT-210; Minerva Neurosciences/Mitsubishi Tanabe Pharma), Evenamide (NW-3509; Newron Pharmaceuticals), NBI-570 (Neurocrine Biosciences/Nxera Pharma), LB-102 (LB Pharmaceuticals), and others.
Teva Pharmaceutical/MedinCell/Royalty Pharma's TEV-'749 (olanzapine) is an investigational, once-monthly, long-acting subcutaneous formulation of the second-generation antipsychotic olanzapine. The product has not received regulatory approval for any indication, and its safety and efficacy have yet to be established. Teva's schizophrenia portfolio has advanced with the development of TEV-'749, a once-monthly subcutaneous long-acting injectable formulation designed to provide sustained olanzapine treatment.
Sumitomo Pharma/Otsuka Pharmaceuticals' Ulotaront (SEP-363856) is an investigational small-molecule, orally administered trace amine-associated receptor 1 (TAAR1) agonist that also exhibits serotonin 5-HT1A agonist activity. Unlike conventional antipsychotics, ulotaront does not bind to dopamine D2 or serotonin 5-HT2A receptors. The drug is being jointly developed and commercialized through a collaboration among Sumitomo Pharma, its U.S. subsidiary Sumitomo Pharma America (SMPA), and Otsuka. SMPA discovered ulotaront in collaboration with PsychoGenics, leveraging a mechanism-independent discovery strategy based partly on the in vivo phenotypic SmartCube platform and associated artificial intelligence algorithms.
Reviva Pharmaceuticals' Brilaroxazine (RP-5063) is a novel chemical entity with potent affinity and selectivity for key serotonin and dopamine receptors implicated in schizophrenia and other psychiatric disorders. The compound acts as a multimodal modulator of serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT7 receptors, as well as dopamine D2, D3, and D4 receptors, and is undergoing clinical development across multiple neuropsychiatric indications. In addition to schizophrenia, brilaroxazine is being investigated for bipolar disorder, major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), and inflammatory conditions, including pulmonary arterial hypertension, idiopathic pulmonary fibrosis, and psoriasis.
Minerva Neurosciences/Mitsubishi Tanabe Pharma's Roluperidone (MIN-101) is being developed by Minerva Neurosciences for the treatment of persistent negative symptoms of schizophrenia, which can remain chronic and substantially affect patients' quality of life and functional outcomes. The drug acts on serotonin and sigma receptors in the brain, which are associated with the regulation of mood, cognition, sleep, and anxiety. Minerva Neurosciences holds a global license for roluperidone from Mitsubishi Tanabe Pharma Corporation, including rights to develop, commercialize, and import the compound, also known as MT-210. Roluperidone has completed Phase III clinical development in the U.S. for the treatment of negative symptoms associated with schizophrenia.
The anticipated launch of these emerging therapies are poised to transform the schizophrenia market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the schizophrenia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the schizophrenia drugs market @ Schizophrenia Therapies
Recent Developments in the Schizophrenia Market
Schizophrenia Epidemiology Segmentation
The schizophrenia epidemiology section provides insights into the historical and current schizophrenia patient pool and forecasted trends for the leading markets. Most schizophrenia patients globally do not receive mental health care. Around 50% of mental hospital patients have schizophrenia, but only 31.3% of those with psychosis receive specialized care.
The schizophrenia treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Schizophrenia Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Schizophrenia Market Size in 2025
USD 8 Billion
Key Schizophrenia Companies
Teva Pharmaceutical, MedinCell, Royalty Pharma, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Newron Pharmaceuticals, Neurocrine Biosciences, Nxera Pharma, LB Pharmaceuticals, Janssen Pharmaceuticals, Alkermes, Luye Pharma, Vanda Pharmaceuticals, Intra-cellular Therapies, Gedeon Richter, AbbVie, Bristol Myers Squibb (Karuna Therapeutics), Zia Labs, and others
Key Schizophrenia Therapies
Olanzapine LAI (TEV-44749/mdc-TJK), Ulotaront (SEP-363856), Brilaroxazine (RP-5063), Roluperidone (MIN-101/MT-210), Evenamide (NW-3509), NBI-570, LB-102, REXULTI/RXULTI, CAPLYTA, LONASEN, ABILIFY MYCITE, UZEDY, FANAPT, LYBALVI, COBENFY, and others
Scope of the Schizophrenia Market Report
Download the report to understand medications used to treat schizophrenia @ Schizophrenia Clinical Trials
Table of Contents
1
Schizophrenia Market Key Insights
2
Schizophrenia Market Report Introduction
3
Schizophrenia Market Overview at a Glance
4
Methodology of Epidemiology and Market
5
Executive Summary
6
Key Events
7
Disease Background and Overview
7.1
Introduction
7.2
Signs and Symptoms
7.3
Risk Factors
7.4
Subtypes of Schizophrenia
7.5
Pathophysiology
7.6
Biomarkers in Schizophrenia
7.7
Diagnosis
7.8
Treatment and Management
7.9
Guidelines
8
Patient Journey
9
Epidemiology and Patient Population
9.1
Key Findings
9.2
Assumptions and Rationale: The 7MM
9.2.1
Prevalent Cases of Schizophrenia
9.2.2
Diagnosed Prevalent Cases of Schizophrenia
9.2.3
Gender-specific Diagnosed Prevalent Cases of Schizophrenia
9.2.4
Severity-specific Diagnosed Prevalent Cases of Schizophrenia
9.3
Total Prevalent Cases of Schizophrenia in the 7MM
9.4
Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM
9.5
The US
9.5.1
Total Prevalent Cases of Schizophrenia in the US
9.5.2
Total Diagnosed Prevalent Cases of Schizophrenia in the US
9.5.3
Gender-specific Diagnosed Prevalent Cases of Schizophrenia in the US
9.5.4
Severity-specific Diagnosed Prevalent Cases of Schizophrenia in the US
9.6
EU4 and the UK
9.7
Japan
10
Marketed Schizophrenia Drugs
10.1
Competitive Landscape of Marketed Drugs
10.2
INVEGA SUSTENNA (XEPLION)/INVEGA TRINZA (TREVICTA)/INVEGA HAFYERA (BYANNLI) (paliperidone palmitate): Janssen Pharmaceuticals
10.2.1
Product Description
10.2.2
Regulatory Milestones
10.2.3
Other Development Activities
10.2.4
Safety and Efficacy
10.3
UZEDY (risperidone): Teva Pharmaceuticals/MedinCell
10.4
RISPERDAL CONSTA (risperidone, long-acting): Alkermes/Janssen Pharmaceuticals
10.5
LONASEN (blonanserin): Sumitomo Pharma
10.6
RYKINDO (risperidone): Luye Pharma
10.7
ABILIFY ASIMTUFII (aripiprazole): Otsuka Pharmaceutical/Lundbeck
10.8
FANAPT (iloperidone): Vanda Pharmaceuticals
10.9
REXULTI/RXULTI (brexpiprazole): Otsuka Pharmaceutical/H. Lundbeck
10.10
CAPLYTA (lumateperone/ITI-007): Intra-cellular Therapies
10.11
VRAYLAR/REAGILA (cariprazine): Gedeon Richter/AbbVie
10.12
LYBALVI (olanzapine and samidorphan): Alkermes
10.13
ARISTADA and ARISTADA INITIO (aripiprazole lauroxil): Alkermes
10.14
PERSERIS (risperidone): DURECT Corporation/Indivior
10.15
SECUADO (asenapine/HP-3070): Noven Pharmaceuticals/Hisamitsu Pharmaceutical
10.16
LATUDA (lurasidone hydrochloride): Sunovion Pharmaceuticals/Sumitomo Dainippon Pharma
10.17
COBENFY (xanomeline–trospium): Bristol Myers Squibb (Karuna Therapeutics)/Royalty Pharma/Zia Labs
List to be continued in the final report.
11
Emerging Schizophrenia Drugs
11.1
Competitive Landscape of Emerging Drugs
11.2
Olanzapine LAI (TEV-44749/mdc-TJK): Teva Pharmaceutical/MedinCell/Royalty Pharma
11.2.1
Drug Description
11.2.2
Other Developmental Activity
11.2.3
Clinical Trials Information
11.2.4
Safety and Efficacy
11.2.5
Analysts' Views
11.3
Ulotaront (SEP-363856): Sumitomo Pharma/Otsuka Pharmaceuticals
11.4
Brilaroxazine (RP-5063): Reviva Pharmaceuticals
11.5
Roluperidone (MIN-101/MT-210): Minerva Neurosciences/Mitsubishi Tanabe Pharma
11.6
Evenamide (NW-3509): Newron Pharmaceuticals
List to be continued in the final report.
12
Schizophrenia Market: 7MM Analysis
12.1
Key Findings
12.2
Key Schizophrenia Market Forecast Assumptions
12.3
Schizophrenia Market Outlook
12.4
Attribute Analysis
12.5
Total Market Size of Schizophrenia in the 7MM
12.6
Total Market Size of Schizophrenia by Therapies in the 7MM
12.7
Market Size of Schizophrenia in the US
12.7.1
Total Market Size of Schizophrenia in the US
12.7.2
The Market Size of Schizophrenia by Therapies in the US
12.8
Market Size of Schizophrenia in EU4 and the UK
12.9
Market Size of Schizophrenia in Japan
13
Key Opinion Leaders' Views
14
SWOT Analysis
15
Unmet Needs
16
Market Access and Reimbursement
16.1
The United States
16.2
In EU4 and the UK
16.3
Japan
17
Bibliography
18
Acronyms and Abbreviations
19
Schizophrenia Market Report Methodology
Related Reports
Schizophrenia Clinical Trial Analysis
Schizophrenia Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key schizophrenia companies, including Sunovion Pharmaceuticals, Denovo BioPharma, Cyclerion Therapeutics, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals, and others.
Cognitive Impairment Associated with Schizophrenia Market
Cognitive Impairment Associated with Schizophrenia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cognitive impairment associated with schizophrenia companies, including Boehringer Ingelheim, Recognify Life Sciences, Alto Neuroscience, MEDRx, Kynexis, Gabather AB, and others.
Bipolar Depression Market
Bipolar Depression Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bipolar depression companies, including Xenon Pharmaceuticals, Autobahn Therapeutics, AbbVie, Alto Neuroscience, NRx Pharmaceuticals, LB Pharmaceuticals, and others.
Alzheimer's Disease Market
Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including ARS Pharmaceuticals, Alfresa Pharma, Roche, Stallergenes Greer, DBV Technologies, Aquestive Therapeutics, Aravax, Siolta Therapeutics, GSK, Cue Biopharma, N-Fold, InnoUp Farma, Allergy Therapeutics, UKKO, Bryn Pharma, Poplar Therapeutics, Inimmune, Novartis (Excellergy), Intrommune Therapeutics, Regeneron Pharmaceuticals, Sanofi, Moonlight Therapeutics, Mabylon AG, Insignis Therapeutics, ALK-Abello, Cambridge Allergy, Prota Therapeutics, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP